Ascend acquires Medical World

Share this article:
Ascend Media reported Thursday that it has agreed to acquire Medical World Communications, tripling its size and vaulting into the big leagues of medical publishing with titles like Physician's Money Digest and Cardiology Review.
No financial terms of the transaction were reported. The parties to the transaction expect a closing to take place within 30-60 days.
Medical World founder, chairman and chief executive Jack Hennessy, who held a 30 percent stake in the company, is stepping down, despite an August vow to stay on after the sale. Ascend president and chief executive Cam Bishop will lead the combined company.
Brokered by Evercore Partners, the sale will see Ascend relieve Medical World's majority-owner, Boston-based Great Hill Partners, of all its interest in the company. The move, coming just weeks after Ascend's acquisition of CME shop SynerMed Communications and Exhibitor Visibility Worldwide, gives the Overland Park, Kansas-based company revenues of roughly  $150 million. The company is financially backed by private equity firms J.P. Morgan Partners and Veronis Suhler Stevenson.
Medical World publishes 50 healthcare, retail, food and beverage titles and operates a healthcare marketing agency, Practice Builders. Medical World ranks fifth among medical publishers by revenue. In 2003, the company agreed to pay the government $3.7 million to settle charges of mail fraud stemming from a whistleblower case alleging padding of circulation numbers on 11 titles prior to their acquisition by Medical World.
Ascend was founded in 2002 by Cam Bishop and two of his colleagues from Intertec Publishing, which was absorbed into Primedia. The firm also owns a stable of gaming trade titles, Pro AV, Expo, SynerMed subsidiary IMED Communications and an events media division.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...